drugset / Trial / NCT04698213
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study aims to test if patients achieving a tumor response with the combination of axitinib plus avelumab, can discontinued the axitinib in order to delay the resistance to the anti VEGFR-TKI and decrease the related toxicity of the combination therapy.
Timeline
- Start
- 2020-10-07
- Primary completion
- 2023-09
- Completion
- 2024-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Axitinib | Small molecule | 5 mg | — |